Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives $494.38 Consensus PT from Analysts

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have received a consensus recommendation of “Moderate Buy” from the twenty-nine research firms that are covering the company, MarketBeat.com reports. Twelve investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $492.10.

A number of equities research analysts have issued reports on VRTX shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 8th. Guggenheim decreased their price objective on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Raymond James Financial initiated coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 2nd. They set a “market perform” rating for the company. Morgan Stanley cut their price objective on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Finally, Wall Street Zen lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $425.57 on Tuesday. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $519.88. The stock has a market cap of $109.11 billion, a price-to-earnings ratio of 30.42 and a beta of 0.43. The firm’s 50 day moving average price is $401.71 and its two-hundred day moving average price is $431.95.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter last year, the business posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts forecast that Vertex Pharmaceuticals will post 15.63 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs acquired 5,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Activest Wealth Management bought a new stake in Vertex Pharmaceuticals in the first quarter valued at about $25,000. Chesapeake Asset Management LLC increased its stake in Vertex Pharmaceuticals by 110.0% in the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after acquiring an additional 33 shares during the period. Clal Insurance Enterprises Holdings Ltd increased its stake in Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares during the period. Access Investment Management LLC bought a new stake in Vertex Pharmaceuticals in the second quarter valued at about $27,000. Finally, Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals in the second quarter valued at about $29,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.